Name | ivabradine |
---|---|
Synonyms |
Ivabradine [INN]
3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one [14C]-Ivabradine 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4,2,0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one UNII-3H48L0LPZQ Ivabradine 3-(3-((((7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one Procoralan 2H-3-Benzazepin-2-one, 3-[3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy- 3-{3-[{[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one Corlanor 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one |
Description | Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity[1][2][3][4]. |
---|---|
Related Catalog | |
In Vivo | Ivabradine (1, 10, 20 mg/kg; i.p.) shows anticonvulsant and neuroprotective action in mice[3]. Ivabradine (5, 10, 20 mg/kg;p.o.; daily for 1 weeks) lowers heart rate in mice with enhanced sympathoadrenergic activities[4]. Animal Model: 25-30 g, 6 weeks male Swiss mice[3] Dosage: 1, 10, 20 mg/kg Administration: I.p.; for 3 days Result: Attenuated PTZ- and PICRO-induced seizures while presented an antioxidant effect in allbrain areas studied, and reduced cleaved caspase-3 expression in the CA1 and DG region of PICRO- and PTZ-treated mice, respectively. Animal Model: 3-4 months transgenic (TG) mice with cardiac-restricted overexpression of b2AR[4] Dosage: 5, 10, 20 mg/kg Administration: P.o; daily for 1 weeks Result: Reduced the maximal HR increase in response to the b-agonist isoproterenol, without modifying the response of contractile parameters at 10 mg/kg. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 626.9±55.0 °C at 760 mmHg |
Molecular Formula | C27H36N2O5 |
Molecular Weight | 468.585 |
Flash Point | 332.9±31.5 °C |
Exact Mass | 468.262421 |
PSA | 60.47000 |
LogP | 3.69 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.560 |
Precursor 8 | |
---|---|
DownStream 1 | |